Shin-Ichi Abe

Shin-Ichi Abe

Auto-generated profile, based on publicly available information

Shin-Ichi Abe

SCOHIA PHARMA Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YMYusuke Moritoh
Yusuke Moritoh
SAShin-Ichi Abe
Shin-Ichi Abe
HAHiroki Akiyama
Hiroki Akiyama
AKAkihiro Kobayashi
Akihiro Kobayashi
RKRyokichi Koyama
Ryokichi Koyama
MWMasanori Watanabe
Masanori Watanabe
Circulating phosphate levels are tightly controlled within a narrow range in mammals. By using a novel small-molecule inhibitor, we show that the enzymatic activity of inositol hexakisphosphate kinases (IP6K) is essential for phosphate regulation in vivo. IP6K inhibition suppressed XPR1, a phosphate exporter, thereby decreasing cellular phosphate export, which resulted in increased intracellular ATP levels. The in vivo inhibition of IP6K decreased plasma phosphate levels without inhibiting gut intake or kidney reuptake of phosphate, demonstrating a pivotal role of IP6K-regulated cellular phosphate export on circulating phosphate levels. IP6K inhibition-induced decrease in intracellular inositol pyrophosphate, an enzymatic product of IP6K, was correlated with phosphate changes. Chronic IP6K inhibition alleviated hyperphosphataemia, increased kidney ATP, and improved kidney functions in chronic kidney disease rats. Our results demonstrate that the enzymatic activity of IP6K regulates circulating phosphate and intracellular ATP and suggest that IP6K inhibition is a potential novel treatment strategy against hyperphosphataemia.

1 August 2019 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
HUHikaru Ueno
Hikaru Ueno
RIRyo Ito
Ryo Ito
SAShin-Ichi Abe
Shin-Ichi Abe
MOMitsugi Ookawara
Mitsugi Ookawara
HMHirohisa Miyashita
Hirohisa Miyashita
YMYusuke Moritoh
Yusuke Moritoh
GPR40/FFA1 receptor is a G-protein-coupled receptor expressed in the pancreatic islets and enteroendocrine cells. Here, we report the pharmacological profiles of SCO-267, a novel full agonist of GPR40. Ca2+ signaling and insulin and glucagon-like peptide-1 (GLP-1) secretion were evaluated in GPR40-expressing CHO, MIN6, and GLUTag cells. Hormone secretions and effects on fasting glucose were tested in rats. Single or repeated dosing effects were evaluated in N-STZ-1.5 rats, diet-induced obese (DIO) rats, and GPR40-knockout (Ffar1-/-) mice. Treatment with SCO-267 activated Gq signaling in both high- and low-FFAR1-expressing CHO cells, stimulated insulin secretion in MIN6 cells, and induced GLP-1 release in GLUTag cells. When administered to normal rats, SCO-267 increased insulin, glucagon, GLP-1, glucose-dependent insulinotropic peptide, and peptide YY (PYY) secretions under non-fasting conditions. These results show the full agonistic property of SCO-267 against GPR40. Hypoglycemia was not induced in SCO-267-treated rats during the fasting condition. In diabetic N-STZ-1.5 rats, SCO-267 was highly effective in improving glucose tolerance in single and 2-week dosing studies. DIO rats treated with SCO-267 for 2 weeks showed elevated plasma GLP-1 and PYY levels, reduced food intake, and decreased body weight. In wild-type mice, SCO-267 induced GLP-1 secretion, food intake inhibition, and body weight reduction; however, these effects were abolished in Ffar1-/- mice, indicating a GPR40-dependent mechanism. In conclusion, SCO-267 stimulated islet and gut hormone secretion, improved glycemic control in diabetic rats, and decreased body weight in obese rats. These data suggest the therapeutic potential of SCO-267 for the treatment of diabetes and obesity.

8 August 2007 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
VFVittorio Fattori
Vittorio Fattori
SAShin‐Ichi Abe
Shin‐Ichi Abe
KKKumiko Kobayashi
Kumiko Kobayashi
LCLucio G. Costa
Lucio G. Costa
RTRyozo Tsuji
Ryozo Tsuji

1 May 2008 in Neurotoxicology and Teratology
Verified
Journal Article
Closed access
RTRyozo Tsuji
Ryozo Tsuji
VFVittorio Fattori
Vittorio Fattori
SAShin-Ichi Abe
Shin-Ichi Abe
LCLucio G. Costa
Lucio G. Costa
KKKumiko Kobayashi
Kumiko Kobayashi

16 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HUHikaru Ueno
Hikaru Ueno
RIRyo Ito
Ryo Ito
SAShin-Ichi Abe
Shin-Ichi Abe
HOHitomi Ogino
Hitomi Ogino
MMMinoru Maruyama
Minoru Maruyama
NNNobuhiro Nishigaki
Nobuhiro Nishigaki
GPR40/FFAR1 is a Gq protein-coupled receptor expressed in pancreatic β cells and enteroendocrine cells, and mediates insulin and incretin secretion to regulate feeding behavior. Several GPR40 full agonists have been reported to reduce food intake in rodents by regulating gut hormone secretion in addition to their potent glucose-lowering effects; however, detailed mechanisms of feeding suppression are still unknown. In the present study, we characterized T-3601386, a novel compound with potent full agonistic activity for GPR40, by using in vitro Ca2+ mobilization assay in Chinese hamster ovary (CHO) cells expressing FFAR1 and in vivo hormone secretion assay. We also evaluated feeding suppression and weight loss after the administration of T-3601386 and investigated the involvement of the vagal nerve in these effects. T-3601386, but not a partial agonist fasiglifam, increased intracellular Ca2+ levels in CHO cells with low FFAR1 expression, and single dosing of T-3601386 in diet-induced obese (DIO) rats elevated plasma incretin levels, suggesting full agonistic properties of T-3601386 against GPR40. Multiple doses of T-3601386, but not fasiglifam, in DIO rats showed dose-dependent weight loss accompanied by feeding suppression and durable glucagon-like peptide-1 elevation, all of which were completely abolished in Ffar1-/- mice. Immunohistochemical analysis in the nuclei of the solitary tract demonstrated that T-3601386 increased the number of c-Fos positive cells, which also disappeared in Ffar1-/- mice. Surgical vagotomy and drug-induced deafferentation counteracted the feeding suppression and weight loss induced by the administration of T-3601386. These results suggest that T-3601386 exerts incretin release and weight loss in a GPR40-dependent manner, and that afferent vagal nerves are important for the feeding suppression induced by GPR40 full agonism. Our novel findings raise the possibility that GPR40 full agonist can induce periphery-derived weight reduction, which may provide benefits such as less adverse effects in central nervous system compared to centrally-acting anti-obesity drugs.

26 March 2017 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
SOSatoru Oka
Satoru Oka
YOYoko Obata
Yoko Obata
SSShuntaro Sato
Shuntaro Sato
KTKenta Torigoe
Kenta Torigoe
MSMiki Sawa
Miki Sawa
TNTomoya Nishino
Tomoya Nishino
BACKGROUND:Endocan is expressed in vascular endothelial cells, and its expression is enhanced following endothelial injury via inflammatory cytokines. Subsequently, endocan is secreted into the circulation. Thus, serum endocan levels are considered a...